Published • loading... • Updated
Edesa Biotech Announces Proposed Public Offering
Edesa said the sale may include pre-funded warrants and a 30-day option for underwriters to buy up to 15% more securities.
- On Wednesday, Edesa Biotech, Inc. commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares.
- Edesa expects gross proceeds of approximately $25.0 million from the offering, intending to use funds for general corporate purposes including research, development, and manufacturing.
- Priced at $5.50 per unit, the offering includes common share warrants carrying an exercise price of $7.50 per share, immediately exercisable upon issuance.
- Guggenheim Securities, LLC serves as sole book-running manager, with Edesa granting underwriters a 30-day option to purchase additional shares and warrants up to 15%.
- The Securities and Exchange Commission declared the shelf registration statement effective on September 9, 2025, providing the regulatory framework for this offering.
Insights by Ground AI
14 Articles
14 Articles
NiagaraFallsReview.ca+3 Reposted by 3 other sources
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i)…
·Niagara Falls, Canada
Read Full Article
Coverage Details
Total News Sources14
Leaning Left7Leaning Right3Center3Last UpdatedBias Distribution54% Left
Bias Distribution
- 54% of the sources lean Left
54% Left
L 54%
C 23%
R 23%
Factuality
To view factuality data please Upgrade to Premium
